Prostate-Specific Antigen Kinetics Effects on Outcomes of Low-Volume Metastatic Prostate Cancer Patients Receiving Androgen Deprivation Therapy

Table 4

Univariate and multivariate analysis of predicting factors for time to CRPC.

Factors	Univariate hazard ratio (95% CI)	value	Multivariate hazard ratio (95% CI)	value
Age
<75	1 (reference)
≥75	0.97 (0.79–1.18)	0.731	—
Gleason grade group
<4	1 (reference)
≥4	1.75 (1.25–2.46)	0.001	—
Initial PSA level, ng/ml
<250	1 (reference)
≥250	1.69 (1.34–2.14)	<0.0001	—
TTN, month
<9	1 (reference)		1 (reference)
≥9	0.27 (0.22–0.33)	<0.0001	0.22 (0.11–0.44)	<0.0001
Nadir PSA level, ng/ml
<1	1 (reference)		1 (reference)
≥1	3.78 (2.93–4.88)	<0.0001	3.11 (2.25–4.29)	<0.0001
PSARR, % (month)
<10	1 (reference)		1 (reference)
≥10	3.76 (2.93–4.81)	<0.0001	0.59 (0.31–1.15)	0.123
TFNTC, month
<5	1 (reference)		1 (reference)
≥5	0.19 (0.15–0.24)	<0.0001	1.37 (0.99–1.89)	0.059
PSADT, month
<3	1 (reference)		1 (reference)
≥3	0.34 (0.26–0.44)	<0.0001	0.34 (0.25–0.48)	<0.0001

TTN: time to PSA nadir, PSARR: PSA reduction rate, TFNTC: time from PSA nadir to CRPC, and PSADT: PSA doubling time.